Population at high risk of developing type 2 diabetes | Lifetime reduction in incident cases of type 2 diabetes, cases | Lifetime reduction in incident cases of type 2 diabetes, % | Lifetime reduction in the average number of years lived with type 2 diabetes, years | Lifetime reduction in the average number of years lived with type 2 diabetes, % | Upfront cost in the first 2 years of implementing the program (€, 2020) | Lifetime total costs of from a healthcare system perspective (€, 2020) | Lifetime incremental costs from a healthcare system perspective (€, 2020) | Lifetime total costs from a societal perspective (€, 2020) | Lifetime incremental costs from a societal perspective (€, 2020) | Lifetime incremental QALYs | |
Total N | Mean % of participating | ||||||||||
Cohort 35–54 years | |||||||||||
2 308 625 | 100% | 26 788 | 2.06 | 0.03 | 0.65 | 745 559 616 | 145 348 605 401 | 381 475 867 | 588 466 202 230 | −98 799 116 | 32 321 |
1 154 312 | 50% | 13 394 | 372 779 646 | 72 674 271 221 | 190 737 851 | 294 233 101 115 | −49 399 537 | 14 572 | |||
577 156 | 25% | 6 697 | 186 389 823 | 36 337 135 611 | 95 368 926 | 147 116 598 239 | −24 699 768 | 6889 | |||
230 862 | 10% | 2 679 | 74 555 800 | 14 534 829 061 | 38 147 504 | 58 846 620 223 | −9 879 890 | 2660 | |||
115 431 | 5% | 1 339 | 37 277 900 | 7 267 414 530 | 19 073 752 | 29 423 262 431 | −4 939 945 | 1314 | |||
Cohort 55–74 years | |||||||||||
6 170 870 | 100% | 15 319 | 3.96 | 0.06 | 0.93 | 1 967 541 011 | 288 717 395 540 | 1 363 007 102 | 298 897 291 524 | 434 170 950 | 168 359 |
3 085 435 | 50% | 7 660 | 983 770 505 | 144 358 697 770 | 681 503 551 | 149 448 581 027 | 217 085 475 | 65 799 | |||
1 542 718 | 25% | 3 830 | 491 885 412 | 72 179 372 279 | 340 751 886 | 74 724 290 514 | 108 542 773 | 28 304 | |||
617 087 | 10% | 1 532 | 196 754 101 | 28 871 739 554 | 136 300 710 | 29 889 664 418 | 43 417 095 | 10 219 | |||
30 854 | 5% | 766 | 98 376 891 | 14 435 846 383 | 68 150 245 | 14 944 832 209 | 21 708 512 | 4 926 |
QALYs, quality-adjusted life years.